Literature DB >> 28853040

State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Latika Puri1, Kerri A Nottage2, Jane S Hankins1, Doralina L Anghelescu3.   

Abstract

Acute vaso-occlusive crisis (VOC) is a hallmark of sickle cell disease (SCD). Multiple complex pathophysiological processes can result in pain during a VOC. Despite significant improvements in the understanding and management of SCD, little progress has been made in the management of pain in SCD, although new treatments are being explored. Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of treatment of VOC pain, but new classes of drugs are being tested to prevent and treat acute pain. Advancements in the understanding of the pathophysiology of SCD and pain and the pharmacogenomics of opioids have yet to be effectively utilized in the management of VOC. Opioid tolerance and opioid-induced hyperalgesia are significant problems associated with the long-term use of opioids, and better strategies for chronic pain therapy are needed. This report reviews the mechanisms of pain associated with acute VOC, describes the current management of VOC, and describes some of the new therapies under evaluation for the management of acute VOC in SCD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28853040     DOI: 10.1007/s40272-017-0263-z

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  117 in total

Review 1.  Evidence-based management of sickle cell disease in the emergency department.

Authors:  Jeffrey Glassberg
Journal:  Emerg Med Pract       Date:  2011-08

2.  Use of ketorolac in sickle-cell disease and vaso-occlusive crisis.

Authors:  E Goodman
Journal:  Lancet       Date:  1991-09-07       Impact factor: 79.321

Review 3.  The molecular pathobiology of cell membrane iron: the sickle red cell as a model.

Authors:  P Browne; O Shalev; R P Hebbel
Journal:  Free Radic Biol Med       Date:  1998-04       Impact factor: 7.376

Review 4.  Fluid replacement therapy for acute episodes of pain in people with sickle cell disease.

Authors:  Uduak Okomo; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2015-03-12

5.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Authors:  Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang
Journal:  Blood       Date:  2005-10-01       Impact factor: 22.113

6.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

7.  Tramadol infusion for the pain management in sickle cell disease: a case report.

Authors:  Elvan Erhan; Mehmet T Inal; Yesim Aydinok; Can Balkan; Ibrahim Yegul
Journal:  Paediatr Anaesth       Date:  2007-01       Impact factor: 2.556

8.  How French paediatric emergency departments manage painful vaso-occlusive episodes in sickle cell disease patients.

Authors:  Caroline Galeotti; Emilie Courtois; Ricardo Carbajal
Journal:  Acta Paediatr       Date:  2014-10-02       Impact factor: 2.299

9.  The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Antonios Bilalis; Eleni Plata; Konstantinos Varvagiannis; George Stamatopoulos; Klio Sinopoulou; Aggeliki Balassopoulou; Dimitris Loukopoulos; Evangelos Terpos
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

10.  Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial.

Authors:  Eduard J van Beers; Charlotte F J van Tuijn; Pythia T Nieuwkerk; Philip W Friederich; Jan H Vranken; Bart J Biemond
Journal:  Am J Hematol       Date:  2007-11       Impact factor: 10.047

View more
  4 in total

1.  Prevalence of neuropathic pain in adolescents with sickle cell disease: A single-center experience.

Authors:  Melissa Cregan; Latika Puri; Guolian Kang; Doralina Anghelescu
Journal:  Pediatr Blood Cancer       Date:  2022-02-11       Impact factor: 3.167

2.  Isolation and Characterisation of Quercitrin as a Potent Anti-Sickle Cell Anaemia Agent from Alchornea cordifolia.

Authors:  Olayemi Adeniyi; Rafael Baptista; Sumana Bhowmick; Alan Cookson; Robert J Nash; Ana Winters; Jianying Shen; Luis A J Mur
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

Review 3.  Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.

Authors:  Martha O Kenney; Wally R Smith
Journal:  J Pain Res       Date:  2022-03-31       Impact factor: 3.133

Review 4.  Treatment Options That Reduce the Duration of Sickle Cell Vaso-Occlusive Crises: A Systematic Review.

Authors:  Adebisi O Akindele; Ana P Jalkh; Aziza K Eastmond; Chaitra Shetty; Syed Muhammad Hannan Ali Rizvi; Joudi Sharaf; Kerry-Ann D Williams; Maha Tariq; Maitri V Acharekar; Sara Elena Guerrero Saldivia; Sumedha N Unnikrishnan; Yeny Y Chavarria; Prachi Balani
Journal:  Cureus       Date:  2022-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.